Clinical Trial Update: VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of VNP40101M for Richter syndrome and refractory/relapsed chronic lymphocytic leukemia or other lymphoproliferative disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Lymphoproliferative Disorders
• Richter Syndrome

Drugs mentioned

• VNP40101M

Snippet

Sponsor: Vion Pharmaceuticals | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: COMPLETED